File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The effects of non-steroidal anti-inflammatory drugs (selective and non-selective) on the treatment of periodontal diseases

TitleThe effects of non-steroidal anti-inflammatory drugs (selective and non-selective) on the treatment of periodontal diseases
Authors
Issue Date2005
PublisherBentham Science Publishers Ltd. The Journal's web site is located at http://www.bentham.org/cpd/index.htm
Citation
Current Pharmaceutical Design, 2005, v. 11 n. 14, p. 1757-1769 How to Cite?
AbstractThe objective was to review the literature on the effects of selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs) on the treatment of periodontal diseases. A search of MEDLINE was conducted and articles published in English until December 2003 were included. The results from in vitro and animal experiments as well as from human clinical trials are presented. Non-selective cyclooxygenase-1 (COX-1) inhibitors used in periodontal research include compounds such as aspirin, flurbiprofen, ibuprofen, naproxen and piroxicam. Selective cyclooxygenase-2 (COX-2) inhibitors represent a new group of pharmaceutical products termed "coxibs" that include meloxicam, nimesulide, etodolac and celecoxib. Evidence from animal experiments and clinical trials documents that selective and non-selective NSAIDs are mainly responsible for the stabilization of periodontal conditions by reducing the rate of alveolar bone resorption. This is achieved through local inhibition of both enzymes (e.g. COX-1 and COX-2) responsible for the synthesis of arachidonic acid metabolites. Evidence shows that the effects of NSAIDs drop off rapidly after drugwithdrawal. One of the major advantages of selective COX-2 inhibition is the reduction of adverse systemic effects. Although some studies present promising results, no data from long-term, multicenter prospective clinical trials are yet available for determining whether these therapeutic effects can be retained on a long-term basis. Many of these compounds, such as flurbiprofen, are readily absorbed through the gingival tissues. Therefore, the development of topical NSAIDs formulations (e.g. gels, toothpastes, rinses) with a daily application seems to be of particular interest. This may help to further reduce adverse systemic effects of non-selective NSAIDs in the long-term host modulation of periodontitis-susceptible patients. © 2005 Bentham Science Publishers Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/154325
ISSN
2015 Impact Factor: 3.052
2015 SCImago Journal Rankings: 1.220
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorSalvi, GEen_US
dc.contributor.authorLang, NPen_US
dc.date.accessioned2012-08-08T08:24:36Z-
dc.date.available2012-08-08T08:24:36Z-
dc.date.issued2005en_US
dc.identifier.citationCurrent Pharmaceutical Design, 2005, v. 11 n. 14, p. 1757-1769en_US
dc.identifier.issn1381-6128en_US
dc.identifier.urihttp://hdl.handle.net/10722/154325-
dc.description.abstractThe objective was to review the literature on the effects of selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs) on the treatment of periodontal diseases. A search of MEDLINE was conducted and articles published in English until December 2003 were included. The results from in vitro and animal experiments as well as from human clinical trials are presented. Non-selective cyclooxygenase-1 (COX-1) inhibitors used in periodontal research include compounds such as aspirin, flurbiprofen, ibuprofen, naproxen and piroxicam. Selective cyclooxygenase-2 (COX-2) inhibitors represent a new group of pharmaceutical products termed "coxibs" that include meloxicam, nimesulide, etodolac and celecoxib. Evidence from animal experiments and clinical trials documents that selective and non-selective NSAIDs are mainly responsible for the stabilization of periodontal conditions by reducing the rate of alveolar bone resorption. This is achieved through local inhibition of both enzymes (e.g. COX-1 and COX-2) responsible for the synthesis of arachidonic acid metabolites. Evidence shows that the effects of NSAIDs drop off rapidly after drugwithdrawal. One of the major advantages of selective COX-2 inhibition is the reduction of adverse systemic effects. Although some studies present promising results, no data from long-term, multicenter prospective clinical trials are yet available for determining whether these therapeutic effects can be retained on a long-term basis. Many of these compounds, such as flurbiprofen, are readily absorbed through the gingival tissues. Therefore, the development of topical NSAIDs formulations (e.g. gels, toothpastes, rinses) with a daily application seems to be of particular interest. This may help to further reduce adverse systemic effects of non-selective NSAIDs in the long-term host modulation of periodontitis-susceptible patients. © 2005 Bentham Science Publishers Ltd.en_US
dc.languageengen_US
dc.publisherBentham Science Publishers Ltd. The Journal's web site is located at http://www.bentham.org/cpd/index.htmen_US
dc.relation.ispartofCurrent Pharmaceutical Designen_US
dc.subject.meshAnimalsen_US
dc.subject.meshAnti-Inflammatory Agents, Non-Steroidal - Therapeutic Useen_US
dc.subject.meshArachidonic Acid - Metabolismen_US
dc.subject.meshBone Resorption - Etiologyen_US
dc.subject.meshGingivitis - Drug Therapyen_US
dc.subject.meshHumansen_US
dc.subject.meshPeriodontal Diseases - Drug Therapy - Etiologyen_US
dc.subject.meshPeriodontium - Metabolismen_US
dc.titleThe effects of non-steroidal anti-inflammatory drugs (selective and non-selective) on the treatment of periodontal diseasesen_US
dc.typeArticleen_US
dc.identifier.emailLang, NP:nplang@hkucc.hku.hken_US
dc.identifier.authorityLang, NP=rp00031en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.2174/1381612053764878en_US
dc.identifier.pmid15892673-
dc.identifier.scopuseid_2-s2.0-18744406713en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-18744406713&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume11en_US
dc.identifier.issue14en_US
dc.identifier.spage1757en_US
dc.identifier.epage1769en_US
dc.identifier.isiWOS:000228912500003-
dc.publisher.placeNetherlandsen_US
dc.identifier.scopusauthoridSalvi, GE=35600695300en_US
dc.identifier.scopusauthoridLang, NP=7201577367en_US
dc.identifier.citeulike175231-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats